All In Biotech

Drug Trial Radar · NCT00510263

Scandinavian Bell's Palsy Study

A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy

Last checked: Nov 19, 2026Latest source record: Jun 4, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 839 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

839

Actual

Start

May 2001

Primary completion

Sep 2007

Study completion Sep 2007

Sponsor

Lead sponsor
Uppsala University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GlaxoSmithKline; Pfizer
First posted
Aug 1, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to study the effects of prednisolone and valaciclovir, with equal importance, compared to placebo for the treatment of Bell´s palsy. The combination of prednisolone and valaciclovir will also be studied.

Conditions

  • Bell's Palsy

Interventions

  • Prednisolone + placeboDrug

    Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.

  • Valaciclovir + placeboDrug

    Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.

  • Prednisolone + valaciclovirDrug

    Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.

  • Placebo + placeboDrug

    Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint will be the time to complete clinical recovery from Bell's palsy.Time frame: 1, 2, 3, 6 or 12 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.